Raxibacumab, a human monoclonal lgC_u antibody, is effective in the treatment of Bacillus anthracis infection or anthrax toxin exposure in animal studies due to its ability to inhibit the binding of B. anthracis protective antigen to its receptor, thereby preventing the entry and activity of anthrax toxin in cells. Raxibacumab was well tolerated and safe, With no dose-limiting adverse events when administered to healthy human volunteers. Results from the animal studies and phase I clinical studies in humans support the development and use of raxibacumab as a novel therapeutic agent for inhalational anthrax.
展开▼
